Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Browse the options below to explore whats available through each partner and find the best fit for your needs
New basic and clinical research is clarifying the mechanistic relevance and therapeutic feasibility of multiple targets within the glutamate system for novel drug discovery, including NMDA and AMPA (-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors, metabotropic glutamate receptors, and other key regulatory proteins such as glycine transporter 1 and excitatory amino acid transporters
Participants self-administered daily subcutaneous injections of tesamorelin (Theratechnologies Inc), a stabilized analog of human GHRH (1 mg/d), or a placebo 30 minutes before bedtime for 20 weeks
Shape changes of erythrocytes during blood clot contraction and the structure of polyhedrocytes
